L-Leucine (amount not specified): An essential amino acid, L-leucine helps preserve lean muscle mass during weight loss, ...

Basel, July 03, 2025 – Novartis today announced top-line results from the Phase III GCAptAIN study evaluating Cosentyx® (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis ...

Une offre de 3,01 $ US en espèces plus un droit conditionnel à la valeur représentant des paiements supplémentaires totaux potentiels pouvant atteindre 1,19 $ US par action La contrepartie initiale et ...

The Transaction will be implemented by way of a plan of arrangement under the Business Corporations Act (Québec) and is expected to close during the Company’s fourth quarter ending November 30, 2025, ...

SANTA YNEZ, Calif., July 02, 2025 (GLOBE NEWSWIRE) -- Raw Garden, California’s leading Clean Green-certified cannabis ...

Building on its acquisition of 15 mining permits located at the Fola Mine Complex in March 2025, the Company has purchased two additional mining permits (“Purchased Permits”) at the site with an ...

The stock options are subject to the terms and conditions of Xilio Therapeutics’ 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the ...

Spartan Capital Securities, LLC acted as exclusive placement agent for the private placement. TroyGould PC acted as counsel to the Company. Kaufman & Canoles, P.C. acted as counsel to Spartan Capital ...

Olema is providing this information in accordance with Nasdaq Listing Rule 5635 (c) (4).

Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today ...

The 2024 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Praxis, or following a bona fide period of non-employment, as an ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...